{"id":7531,"date":"2025-04-10T09:06:08","date_gmt":"2025-04-10T09:06:08","guid":{"rendered":"https:\/\/tst.incliva.es\/?page_id=7531"},"modified":"2025-04-10T09:06:08","modified_gmt":"2025-04-10T09:06:08","slug":"ana-lluch-hernandez","status":"publish","type":"page","link":"https:\/\/tst.incliva.es\/en\/ana-lluch-hernandez\/","title":{"rendered":"Ana Lluch Hern\u00e1ndez"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container fusion-parallax-none nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #ededed;background-image: url(&quot;https:\/\/www.incliva.es\/wp-content\/uploads\/2021\/01\/fondo.jpg&quot;);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_3_4 3_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-1\" style=\"transform:translate3d(0,0,0);\"><h3>Dr. Ana Lluch Hern\u00e1ndez<\/h3>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:3px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-2\" style=\"transform:translate3d(0,0,0);\"><h5><span style=\"color: #3D44AC;\">Principal Investigator<br \/>\nResearch Group on Breast Cancer Biology<br \/>\n<\/span><\/h5>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-3\" style=\"transform:translate3d(0,0,0);\"><h4 style=\"text-align: justify;\">Presentation<\/h4>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-0{width:75% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 2.56%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 2.56%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-0{width:75% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 2.56%;margin-left : 2.56%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-0{width:100% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#ffffff;border-width: 0 0 0 2px;border-color:#9da0d2;border-style:solid;padding: 4% 4% 4% 4%;\">\n<div ><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-none\" style=\"border-radius:5px;\"><img src=\"\/wp-content\/uploads\/2022\/10\/Ana-Lluch-Hernandez_FIH12_IP.jpg\" class=\"img-responsive\"\/><\/span><\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:10px;margin-bottom:10px;width:100%;\"><\/div>\n<div class=\"fusion-text fusion-text-4\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: center;\">Principal<br \/>\nInvestigator<\/h5>\n<div style=\"text-align: center;\">Dr. Ana Lluch Hern\u00e1ndez<\/div>\n<p style=\"text-align: center;\"><a href=\"mailto:ana.lluch@uv.es\">ana.lluch@uv.es<\/a><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-1{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-1 > .fusion-column-wrapper {padding-top : 4% !important;padding-right : 4% !important;margin-right : 7.68%;padding-bottom : 4% !important;padding-left : 4% !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-1{width:25% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-1{width:100% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-fullwidth.fusion-builder-row-1 { overflow:visible; }.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e5e5e5;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-5\" style=\"transform:translate3d(0,0,0);\"><h5>Publications<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-1 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-1 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-1 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav,.fusion-tabs.fusion-tabs-1 .nav-tabs,.fusion-tabs.fusion-tabs-1 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-af25136cddad13f3b87\" aria-selected=\"true\" id=\"fusion-tab-2023\" href=\"#tab-af25136cddad13f3b87\"><h4 class=\"fusion-tab-heading\">2023<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-747a99d9fe137bc99a7\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2022\" href=\"#tab-747a99d9fe137bc99a7\"><h4 class=\"fusion-tab-heading\">2022<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-273eb7021fe60612771\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2021\" href=\"#tab-273eb7021fe60612771\"><h4 class=\"fusion-tab-heading\">2021<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-af25136cddad13f3b87\" aria-selected=\"true\" id=\"mobile-fusion-tab-2023\" href=\"#tab-af25136cddad13f3b87\"><h4 class=\"fusion-tab-heading\">2023<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2023\" id=\"tab-af25136cddad13f3b87\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nAuthor Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Schettini F, Chic N, Bras\u00f3-Maristany F, Par\u00e9 L, Pascual T, Conte B, Mart\u00ednez-S\u00e1ez O, Adamo B, Vidal M, Barnadas E, Fern\u00e1ndez-Martinez A, Gonz\u00e1lez-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavil\u00e1 J, Barrios CH, Lluch A, Mart\u00edn M, Locci M, De Placido S, Prat A. NPJ Breast Cancer. 2023 Apr 29;9(1):32. doi: <a href='https:\/\/doi.org\/10.1038\/s41523-023-00538-x' target='_blank'>10.1038\/s41523-023-00538-x<\/a>. Erratum for: NPJ Breast Cancer. 2021 Jan 4;7(1):1. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37120452' target='_blank'>37120452<\/a><\/p>\n<p>Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical Anti-HER therapies. Tapia M, Hernando C, Mart\u00ednez M, Burgu\u00e9s O, Tebar-S\u00e1nchez C, Lameirinhas A, Agreda-Roca A, Torres-Ruiz S, Garrido-Cano I, Lluch A, Bermejo B, Eroles P. Cancers. 2023 Sep 12;15(18):4522. doi: <a href='https:\/\/doi.org\/10.3390\/cancers15184522' target='_blank'>10.3390\/cancers15184522<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37760491' target='_blank'>37760491<\/a><\/p>\n<p>Delivery of miR-200c-3p using tumor-targeted mesoporous silica nanoparticles for breast cancer therapy. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. ACS Applied Materials &#038; Interfaces. 2023 Aug 16;15(32):38323-38334. doi: <a href='https:\/\/doi.org\/10.1021\/acsami.3c07541' target='_blank'>10.1021\/acsami.3c07541<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37549382' target='_blank'>37549382<\/a><\/p>\n<p>Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells. Oltra S, Colomo S, Sin L, Perez-Lopez M, Lazaro S, Molina-Crespo A, Choi K, Ros-Pardo D, Martinez L, Morales S, Gonzalez-Paramos C, Orantes A, Soriano M, Hernandez A, Lluch A, Rojo F, Albanell J, Gomez-Puertas P, Ko J, Sarrio D, Moreno-Bueno G. Cell Death and Differentiation. 2023 May;30(5):1366-1381. doi: <a href='https:\/\/doi.org\/10.1038\/s41418-023-01143-y' target='_blank'>10.1038\/s41418-023-01143-y<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36899106' target='_blank'>36899106<\/a><\/p>\n<p>Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis. Vazquez J, Antolin S, Ruiz-Borrego M, Servitja S, Alba E, Barnadas A, Lluch A, Martin M, Rodriguez-Lescure A, Sola I, Bonfill X, Urrutia G, Sanchez-Rovira P. Clinical &#038; Translational Oncology. 2022 Nov 22. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-022-02998-2' target='_blank'>10.1007\/s12094-022-02998-2<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36417083' target='_blank'>36417083<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7531-1 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7531-1 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7531-1.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7531-1 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7531-1 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7531-1 .panel-title a:hover, #accordion-7531-1 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7531-1 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7531-1 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7531-1\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"1a0d91e015c1acbbf\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7531-1\" data-target=\"#1a0d91e015c1acbbf\" href=\"#1a0d91e015c1acbbf\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2023<\/span><\/a><\/h4><\/div><div id=\"1a0d91e015c1acbbf\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nHigh VEGFR3 expression reduces doxorubicin efficacy in triple-negative breast cancer. Torres Ruiz S, Tormo E, Garrido Cano I, Lameirinhas A, Rojo F, Madoz Gurpide J, Burgues O, Hernando C, Bermejo B, Martinez MT, Lluch A, Cejalvo JM, Eroles P. International Journal of Molecular Sciences. 2023 Feb 10;24(4):3601. doi: <a href='https:\/\/doi.org\/10.3390\/ijms24043601' target='_blank'>10.3390\/ijms24043601<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36835014' target='_blank'>36835014<\/a><\/p>\n<p>miR-146a-5p promotes angiogenesis and confers trastuzumab resistance in HER2+ breast cancer. Cabello P, Torres-Ruiz S, Adam-Artigues A, Fores-Martos J, Martinez M, Hernando C, Zazo S, Madoz-Gurpide J, Rovira A, Burgues O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo J, Eroles P. Cancers. 2023 Apr 4;15(7):2138. doi: <a href='https:\/\/doi.org\/10.3390\/cancers15072138' target='_blank'>10.3390\/cancers15072138<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37046799' target='_blank'>37046799<\/a><\/p>\n<p>Physicians&#8217; attitudes and perceived barriers to adherence to the national breast cancer clinical practice guidelines in Mexico: a survey study. Martinez-Cannon B, Soto-Perez-de-Celis E, Valle-Solis A, Arce-Salinas C, Bargallo-Rocha E, Bautista-Pina V, Cervantes-Sanchez G, Flores-Balcazar C, Tamburrino M, Lluch A, Maffuz-Aziz A, Perez-Sanchez V, Poitevin-Chacon A, Salas-Gonzalez E, Torres L, Valero V, Villasenor-Navarro Y, Cardenas-Sanchez J. Clinical &#038; Translational Oncology. 2023 Jan;25(1):151-159. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-022-02921-9' target='_blank'>10.1007\/s12094-022-02921-9<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35986133' target='_blank'>35986133<\/a><\/p>\n<p>Real-world use of highly sensitive liquid biopsy monitoring in metastatic breast cancer patients treated with endocrine agents after exposure to aromatase inhibitors. Fuentes-Antr\u00e1s J, Mart\u00ednez-Rodr\u00edguez A, Guevara-Hoyer K, L\u00f3pez-Cade I, Lorca V, Pascual A, de Luna A, Ramirez-Ruda C, Swindell J, Flores P, Lluch A, Cescon D, P\u00e9rez-Segura P, Ocana A, Jones F, Moreno F, Garc\u00eda-Barber\u00e1n V, Garc\u00eda-S\u00e1enz J. International Journal of Molecular Sciences. 2023 Jul 13;24(14):11419. doi: <a href='https:\/\/doi.org\/10.3390\/ijms241411419' target='_blank'>10.3390\/ijms241411419<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37511178' target='_blank'>37511178<\/a><\/p>\n<p>The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review. Vazquez JC, Pinero A, de Castro FJ, Lluch A, Martin M, Barnadas A, Alba E, Rodriguez-Lescure A, Rojo F, Gimenez J, Sola I, Quintana MJ, Bonfill X, Urrutia G, Sanchez-Rovira P. Clinical &#038; Translational Oncology. 2023 Feb;25(2):417-428. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-022-02953-1' target='_blank'>10.1007\/s12094-022-02953-1<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36153763' target='_blank'>36153763<\/a><\/p>\n<p>Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine. Asleh K, Lluch A, Goytain A, Barrios C, Wang X, Torrecillas L, Gao D, Ruiz-Borrego M, Leung S, Bines J, Guerrero-Zotano A, Garcia-Saenz J, Cejalvo J, Herranz J, Torres R, de la Haba-Rodriguez J, Ayala F, Gomez H, Rojo F, Nielsen T, Martin M. Clinical Cancer Research. 2023 Jan 17;29(2):389-400. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2191' target='_blank'>10.1158\/1078-0432.CCR-22-2191<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36346687' target='_blank'>36346687<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-747a99d9fe137bc99a7\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2022\" href=\"#tab-747a99d9fe137bc99a7\"><h4 class=\"fusion-tab-heading\">2022<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2022\" id=\"tab-747a99d9fe137bc99a7\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nDevelopment of a Novel NGS methodology for ultrasensitive circulating tumor dna detection as a tool for early-stage breast cancer diagnosis. Jimenez-Rodriguez B, Alba-Bernal A, Lopez-Lopez E, Quiros-Ortega ME, Carbajosa G, Garrido-Aranda A, Alvarez M, Godoy-Ortiz A, Queipo-Ortuno MI, Vicioso L, Diaz-Cordoba G, Roldan-Diaz MD, Velasco-Suelto J, Hernando C, Bermejo B, Julve-Parreno A, Lluch A, Pascual J, Comino-Mendez I, Alba E. International Journal of Molecular Sciences. 2022 Dec 21;24(1):146. doi: <a href='https:\/\/doi.org\/10.3390\/ijms24010146' target='_blank'>10.3390\/ijms24010146<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36613590' target='_blank'>36613590<\/a><\/p>\n<p>Immunological landscape of HER-2 positive breast cancer. Moragon S, Hernando C, Martinez-Martinez M, Tapia M, Ortega-Morillo B, Lluch A, Bermejo B, Cejalvo J. Cancers. 2022 Jun 28;14(13):3167. doi: <a href='https:\/\/doi.org\/10.3390\/cancers14133167' target='_blank'>10.3390\/cancers14133167<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35804943' target='_blank'>35804943<\/a><\/p>\n<p>miR-99a-5p modulates doxorubicin resistance via the COX-2\/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Rojo F, Zazo S, Madoz-Gurpide J, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. Cancer Communications. 2022 Dec;42(12):1412-1416. doi: <a href='https:\/\/doi.org\/10.1002\/cac2.12352' target='_blank'>10.1002\/cac2.12352<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35997029' target='_blank'>35997029<\/a><\/p>\n<p>mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer. Casadevall D, Hernandez-Prat A, Garc A-Alonso S, Arpi-Llucia O, Menendez S, Qin M, Guardia C, Morancho B, Sanchez-Mart N F, Zazo S, Gavilan E, Sabbaghi M, Eroles P, Cejalvo J, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Molecular Cancer Research. 2022 Jul 6;20(7):1108-1121. doi: <a href='https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0545' target='_blank'>10.1158\/1541-7786.MCR-21-0545<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35348729' target='_blank'>35348729<\/a><\/p>\n<p>Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. Mouron S, Bueno MJ, Lluch A, Manso L, Calvo I, Cortes J, Garcia-Saenz JA, Gil-Gil M, Martinez-Janez N, Apala JV, Caleiras E, Xim\u00e9nez-Emb\u00fan P, Mu\u00f1oz J, Gonzalez-Cortijo L, Murillo R, S\u00e1nchez-Bayona R, Cejalvo JM, G\u00f3mez-L\u00f3pez G, Fustero-Torre C, Sabroso-Lasa S, Malats N, Martinez M, Moreno A, Megias D, Malumbres M, Colomer R, Quintela-Fandino M. Nature Communications. 2022 Dec 7;13(1):7529. doi: <a href='https:\/\/doi.org\/10.1038\/s41467-022-35065-z' target='_blank'>10.1038\/s41467-022-35065-z<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36477027' target='_blank'>36477027<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7531-2 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7531-2 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7531-2.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7531-2 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7531-2 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7531-2 .panel-title a:hover, #accordion-7531-2 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7531-2 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7531-2 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7531-2\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"d13d1346052bcad6e\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7531-2\" data-target=\"#d13d1346052bcad6e\" href=\"#d13d1346052bcad6e\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2022<\/span><\/a><\/h4><\/div><div id=\"d13d1346052bcad6e\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nTargeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Adam-Artigues A, Arenas E, Martinez-Sabadell A, Braso-Maristany F, Cervera R, Tormo E, Hernando C, Martinez M, Carbonell-Asins J, Simon S, Poveda J, Moragon S, Zazo S, Martinez D, Rovira A, Burgues O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo J. Science Advances. 2022 May 20;8(20):eabk2746. doi: <a href='https:\/\/doi.org\/10.1126\/sciadv.abk2746' target='_blank'>10.1126\/sciadv.abk2746<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35594351' target='_blank'>35594351<\/a><\/p>\n<p>The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview. Vazquez J, Pinero A, de Castro F, Lluch A, Martin M, Barnadas A, Alba E, Rodriguez-Lescure A, Rojo F, Gimenez J, Sola I, Quintana M, Bonfill X, Urrutia G, Sanchez-Rovira P. Clinical &#038; Translational Oncology. 2022 Sep;24(9):1744-1754. doi: <a href='https:\/\/doi.org\/10.1007\/s12094-022-02824-9' target='_blank'>10.1007\/s12094-022-02824-9<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35414152' target='_blank'>35414152<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-273eb7021fe60612771\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2021\" href=\"#tab-273eb7021fe60612771\"><h4 class=\"fusion-tab-heading\">2021<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2021\" id=\"tab-273eb7021fe60612771\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nCircadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression. Fores-Martos J, Cervera-Vidal R, Sierra-Roca J, Lozano-Asencio C, Fedele V, Cornelissen S, Edvarsen H, Tadeo-Cervera I, Eroles P, Lluch A, Tabares-Seisdedos R, Falco A, Van&#8217;t Veer LJ, Schmidt M, Quigley DA, Borresen-Dale AL, Kristensen VN, Balmain A, Climent J. NPJ Breast Cancer. 2021 Sep 10;7(1):118. doi: <a href='https:\/\/doi.org\/10.1038\/s41523-021-00329-2' target='_blank'>10.1038\/s41523-021-00329-2<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34508103' target='_blank'>34508103<\/a><\/p>\n<p>Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer. Adam-Artigues A, Garrido-Cano I, Simon S, Ortega B, Moragon S, Lameirinhas A, Constancio V, Salta S, Burgues O, Bermejo B, Henrique R, Lluch A, Jeronimo C, Eroles P, Cejalvo J. ESMO Open. 2021 Jan 18;6(1):100039. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2020.100039' target='_blank'>10.1016\/j.esmoop.2020.100039<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33477007' target='_blank'>33477007<\/a><\/p>\n<p>Fertility and breast cancer: a literature review of counseling, preservation options and outcomes. Moragon S, Di Liello R, Bermejo B, Hernando C, Olcina E, Chirivella I, Lluch A, Cejalvo JM, Martinez MT, Critical Reviews In Oncology\/Hematology. 2021 Aug 27;166:103461. doi: <a href='https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103461' target='_blank'>10.1016\/j.critrevonc.2021.103461<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34461268' target='_blank'>34461268<\/a><\/p>\n<p>Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool. Garrido-Cano I, Pla L, Santiago-Felipe S, Simon S, Ortega B, Bermejo B, Lluch A, Cejalvo J, Eroles P, Martinez-Manez R. ACS Sensors. 2021 Mar 26;6(3):1022-1029. doi: <a href='https:\/\/doi.org\/10.1021\/acssensors.0c02222' target='_blank'>10.1021\/acssensors.0c02222<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33599490' target='_blank'>33599490<\/a><\/p>\n<p>Oral Selective Estrogen Receptor Degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Hernando C, Ortega-Morillo B, Tapia M, Moragon S, Martinez M, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B, Cejalvo J. International Journal of Molecular Sciences. 2021 Jul 22;22(15):7812. doi: <a href='https:\/\/doi.org\/10.3390\/ijms22157812' target='_blank'>10.3390\/ijms22157812<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34360578' target='_blank'>34360578<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7531-3 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7531-3 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7531-3.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7531-3 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7531-3 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7531-3 .panel-title a:hover, #accordion-7531-3 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7531-3 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7531-3 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7531-3\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"7cf6de6326c372d05\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7531-3\" data-target=\"#7cf6de6326c372d05\" href=\"#7cf6de6326c372d05\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2021<\/span><\/a><\/h4><\/div><div id=\"7cf6de6326c372d05\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nPreclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer. Guardia C, Bianchini G, Arpi-LLucia O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero J, Soria-Jimenez L, Sabbaghi M, Pena R, Madoz-Gurpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Clinical Cancer Research. 2021 Sep 15;27(18):5096-5108. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2915' target='_blank'>10.1158\/1078-0432.CCR-20-2915<\/a>. PMID:<a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34385295' target='_blank'>34385295<\/a><\/p>\n<p>Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S. NPJ Breast Cancer. 2021 Apr 16;7(1):44. doi: <a href='https:\/\/doi.org\/10.1038\/s41523-021-00251-7' target='_blank'>10.1038\/s41523-021-00251-7<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33863913' target='_blank'>33863913<\/a><\/p>\n<p>Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. Martinez MT, Monton-Bueno J,  Simon S, Ortega B, Moragon S, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. ESMO open. 2021 May 11;6(3):100148. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100148' target='_blank'>10.1016\/j.esmoop.2021.100148<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33989988' target='_blank'>33989988<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-2{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-2 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-2{width:100% !important;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-2{width:100% !important;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-2{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-3 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #9da0d2;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-6\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: left;\">Projects<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-2 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-2 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-2 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav,.fusion-tabs.fusion-tabs-2 .nav-tabs,.fusion-tabs.fusion-tabs-2 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-d5d11e41208e05826e0\" aria-selected=\"true\" id=\"fusion-tab-projects\" href=\"#tab-d5d11e41208e05826e0\"><h4 class=\"fusion-tab-heading\">PROJECTS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-d5d11e41208e05826e0\" aria-selected=\"true\" id=\"mobile-fusion-tab-projects\" href=\"#tab-d5d11e41208e05826e0\"><h4 class=\"fusion-tab-heading\">PROJECTS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-projects\" id=\"tab-d5d11e41208e05826e0\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:left;\">\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>CB16\/12\/00481<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>CIBER C\u00e1ncer de mama<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Ana Lluch Hern\u00e1ndez, Emilio Alba Conejo<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2017 &#8211; 2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-3{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-3 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-3{width:100% !important;order : 0;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-3{width:100% !important;order : 0;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-3{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-4 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e5e5e5;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-7\" style=\"transform:translate3d(0,0,0);\"><h5>+ Info<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-3 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-3 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-3 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav,.fusion-tabs.fusion-tabs-3 .nav-tabs,.fusion-tabs.fusion-tabs-3 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-00b234d522f06379a92\" aria-selected=\"true\" id=\"fusion-tab-thesis\" href=\"#tab-00b234d522f06379a92\"><h4 class=\"fusion-tab-heading\">THESIS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-00b234d522f06379a92\" aria-selected=\"true\" id=\"mobile-fusion-tab-thesis\" href=\"#tab-00b234d522f06379a92\"><h4 class=\"fusion-tab-heading\">THESIS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-thesis\" id=\"tab-00b234d522f06379a92\"><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Overcoming resistance to HER2 blockade in breast cancer: AXL as a promising druggable target and prognostic biomarker<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Adam Artigues, Anna<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Lluch Hern\u00e1ndez, Ana; Eroles Asensio, Pilar<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>12\/04\/2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Estudio de las alteraciones gen\u00e9ticas asociadas con la resistencia al tratamiento neoadyuvante de deprivaci\u00f3n estrog\u00e9nica en c\u00e1ncer de mama<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Guerrero Zotano, \u00c1ngel Luis<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>L\u00f3pez Guerrero, Jos\u00e9 Antonio; Guillem Porta, Vicente; Lluch Hern\u00e1ndez, Ana<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>21\/01\/2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Implicaciones del MAMMI-PET en el diagn\u00f3stico y tratamiento del c\u00e1ncer de mama. Comparaci\u00f3n con los resultados anatomopatol\u00f3gicos y con otras pruebas de imagen<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>De Andr\u00e9s G\u00f3mez, Alejandra<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Fuster Diana, Carlos Alberto; Villalba Ferrer, Francisco Leopoldo; Lluch Hern\u00e1ndez, Ana<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>16\/10\/2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Epigenetic regulation of resistance to treatments in triple negative and HER2+ breast cancer: mirnas involved<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Cabello Navarro, Paula<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Erol\u00e9s Asensio, Pilar; Lluch Hern\u00e1ndez, Ana<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>28\/09\/2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat Polit\u00e8cnica de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Evaluaci\u00f3n de los cambios en la respuesta linfocitaria en el microambiente tumoral como factor pron\u00f3stico y predictivo de respuesta a la quimioterapia neoadyuvante del c\u00e1ncer de mama triple negativo estadio ii-iii<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Herrero Vicent, Carmen<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Ruiz Sim\u00f3n, Amparo; Calatrava Fons, Ana; Guillem Porta, Vicente; Lluch Hern\u00e1ndez, Ana<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>27\/05\/2019<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Identificaci\u00f3n de biomarcadores circulantes con valor pron\u00f3stico y predictivo de respuesta en c\u00e1ncer de mama triple negativo<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Salvador Coloma, Carmen<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Lluch Hern\u00e1ndez, Ana; Santaballa Bertr\u00e1n, Ana Mar\u00eda; Font de Mora Sainz, Jaime<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>10\/05\/2019<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Identificaci\u00f3n de los factores cl\u00ednico-patol\u00f3gicos relacionados con la obtenci\u00f3n de la respuesta completa patol\u00f3gica en pacientes con c\u00e1ncer de mama tratadas con quimioterapia neoadyuvante. Validaci\u00f3n del residual cancer burden (rcb) como factor pron\u00f3stico<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Pons Sanz, Vanesa<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Lluch Hern\u00e1ndez, Ana; P\u00e9rez Fidalgo, Jose Alejandro; Burgu\u00e9s Gasi\u00f3n, Octavio<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>02\/04\/2019<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Study of the epi-\/genomic dysregulation of breast cancer in women under 35 years and evaluation of cellular models<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Oltra Sanchis, Sara<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Ribas Despuig, Gloria; Lluch Hern\u00e1ndez, Ana<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>18\/01\/2019<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-4{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-4 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-4{width:100% !important;order : 0;}.fusion-builder-column-4 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-4{width:100% !important;order : 0;}.fusion-builder-column-4 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-4{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/7531"}],"collection":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/comments?post=7531"}],"version-history":[{"count":0,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/7531\/revisions"}],"wp:attachment":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/media?parent=7531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}